Intravitreal Anti-vascular Endothelial Growth Factor versus Observation in Acute Central Serous Chorioretinopathy: One-year Results
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observationfor treating acute central serous chorioretinopathy (CSC). Methods: A retrospective study of 36 patients with acute CSC, including 21 patients treated with anti-VEGF (anti-VEGF group) and 15 patients with observation (observation group). Patients in the anti-VEGF group receiveda single dose of bevacizumab or ranibizumab at baseline. Best-corrected visual acuity (BCVA), central fovealthickness (CFT) and resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) were assessed. The integrity of the foveal inner segment/outer segment (IS/OS) line at 12 months was also analyzed. Results: Resolution of SRF was achieved in 20 of 21 eyes in the anti-VEGF group and in 12 of 15 eyes in theobservation group (p = 0.151). Mean BCVA and CFT were not different between the two groups at 12 months (p> 0.05). The amount of change in BCVA, however, differed significantly between the groups (p = 0.044). FinalOCT more frequently detected the foveal IS/OS line in the anti-VEGF group than in the observation group (p =0.012). Conclusions: In terms of BCVA, anti-VEGF and observation only had similar therapeutic effects in acute CSCpatients. In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptordegeneration and improve long-term visual acuity.
Abstract
Purpose: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observationfor treating acute central serous chorioretinopathy (CSC). Methods: A retrospective study of 36 patients with acute CSC, including 21 patients treated with anti-VEGF (anti-VEGF group) and 15 patients with observation (observation group). Patients in the anti-VEGF group receiveda single dose of bevacizumab or ranibizumab at baseline. Best-corrected visual acuity (BCVA), central fovealthickness (CFT) and resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) were assessed. The integrity of the foveal inner segment/outer segment (IS/OS) line at 12 months was also analyzed. Results: Resolution of SRF was achieved in 20 of 21 eyes in the anti-VEGF group and in 12 of 15 eyes in theobservation group (p = 0.151). Mean BCVA and CFT were not different between the two groups at 12 months (p> 0.05). The amount of change in BCVA, however, differed significantly between the groups (p = 0.044). FinalOCT more frequently detected the foveal IS/OS line in the anti-VEGF group than in the observation group (p =0.012). Conclusions: In terms of BCVA, anti-VEGF and observation only had similar therapeutic effects in acute CSCpatients. In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptordegeneration and improve long-term visual acuity.
참고문헌 (34)
- Levine R, "Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography", Ophthalmology, 96, pp.854~859 (1989)
- Hussain D, "Idiopathic central serous chorioretinopathy", Indian J Ophthalmol, 46, pp.131~137 (1998)
- Loo RH, "Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy", Retina, 22, pp.19~24 (2002)
- Robertson DM, "Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy", Am J Ophthalmol, 95, pp.457~466 (1983)
- Taban M, "Chronic central serous chorioretinopathy: photodynamic therapy", Am J Ophthalmol, 137, pp.1073~1080 (2004)
- Hayashi K, "Indocyanine green angiography of central serous chorioretinopathy", Int Ophthalmol, 9, pp.37~41 (1986)
- Prunte C, "Indocyanine green angiographic findings in central serous chorioretinopathy", Int Ophthalmol, 19, pp.77~82 (1995)
- Prunte C, "Choroidal capillary and venous congestion in central serous chorioretinopathy", Am J Ophthalmol, 121, pp.26~34 (1996)
- Burumcek E, "Laser photocoagulation for persistent central serous retinopathy:results of long-term follow-up", Ophthalmology, 104, pp.616~622 (1997)
- Robertson DM, "Argon laser photocoagulation treatment in central serous chorioretinopathy", Ophthalmology, 93, pp.972~974 (1986)
- Cardillo Piccolino F, "Photodynamic therapy for chronic central serous chorioretinopathy", Retina, 23, pp.752~763 (2003)
- Yannuzzi LA, "Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study", Retina, 23, pp.288~298 (2003)
- Chan WM, "Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin:a novel treatment at the primary disease level", Br J Ophthalmol, 87, pp.1453~1458 (2003)
- Colucciello M, "Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy", Retina, 26, pp.239~242 (2006)
- Stanga PE, "Indocyanine green angiography in chorioretinal diseases: indications and interpretation:an evidence-based update", Ophthalmology, 110, pp.15~21 (2003)
- Torres-Soriano ME, "A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports)", Graefes Arch Clin Exp Ophthalmol, 246, pp.1235~1239 (2008)
- Lim JW, "The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy", Graefes Arch Clin Exp Ophthalmol, 249, pp.969~974 (2011)
- Yannuzzi LA, "Type-A behavior and central serous chorioretinopathy", Retina, 7, pp.111~131 (1987)
- Kanyange ML, "Long-term follow-up of central serous chorioretinopathy (CSCR)", Bull Soc Belge Ophtalmol, (284), pp.39~44 (2002)
- Piccolino FC, "Central serous chorioretinopathy and indocyanine green angiography", Retina, 14, pp.231~242 (1994)
- Lim JW, "Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8in patients with central serous chorioretinopathy", Retina, 30, pp.1465~1471 (2010)
- Seong HK, "Intravitreal bevacizumab to treat acute central serous chorioretinopathy: shortterm effect", Ophthalmologica, 223, pp.343~347 (2009)
- Lim SJ, "Intravitreal bevacizumab injection for central serous chorioretinopathy", Retina, 30, pp.100~106 (2010)
- Lantry LE, "Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications", Curr Opin Mol Ther, 9, pp.592~602 (2007)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Kokame GT, "Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy:6-month results", Br J Ophthalmol, 94, pp.297~301 (2010)
- Brown DM, "Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study", Ophthalmology, 118, pp.1594~1602 (2011)
- Gomi F, "Polypoidal choroidal vasculopathy and treatments", Curr Opin Ophthalmol, 19, pp.208~212 (2008)
- Smretschnig E, "Half-fluence photodynamic therapy in acute central serous chorioretinopathy", Retina, 32, pp.2014~2019 (2012)
- Zhao MW, "Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin", Retina, 29, pp.1155~1161 (2009)
- Chan WM, "Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy:one-year results of a randomized controlled trial", Ophthalmology, 115, pp.1756~1765 (2008)
- Drexler W, "Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography", Arch Ophthalmol, 121, pp.695~706 (2003)
- Ko TH, "Comparison of ultrahigh-and standard-resolution optical coherence tomography for imaging macular hole pathology and repair", Ophthalmology, 111, pp.2033~2043 (2004)
- Matsumoto H, "Elongation of photoreceptor outer segment in central serous chorioretinopathy", Am J Ophthalmol, 145, pp.162~168 (2008)